Welcome to our dedicated page for ReShape Lifesciences news (Ticker: RSLS), a resource for investors and traders seeking the latest updates and insights on ReShape Lifesciences stock.
ReShape Lifesciences Inc. (RSLS) reported company developments tied to weight loss and metabolic health products for obesity and metabolic disease. Its product references include the FDA-approved Lap-Band System for minimally invasive obesity treatment, the investigational Diabetes Bloc-Stim Neuromodulation system using vagus nerve block and stimulation technology for type 2 diabetes and metabolic disorders, and Obalon balloon technology for a swallowable intragastric balloon approach.
Recurring RSLS news categories include clinical and regulatory disclosures, intellectual-property updates for intragastric balloon systems, surgeon education around Lap-Band, shareholder voting matters, governance items, material agreements, security-structure disclosures, and capital-structure actions.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
ReShape Lifesciences (Nasdaq: RSLS) announced it will showcase data on its innovative Diabetes Bloc-Stim Neuromodulation (DBSN) device at the Keystone Symposia on Type 2 Diabetes from May 1-4, 2023, in Palm Springs, CA. The DBSN device aims to improve glycemic control in patients with early-stage diabetes by utilizing sub-diaphragmatic vagus nerve neuromodulation. Study results indicate significant improvements in glycemic control, allowing Fasting Plasma Glucose to decrease from an average of 102 mg/dL to 74 mg/dL. A survey showed that 82% of type 2 diabetes patients interested in lifestyle changes would consider a device like DBSN. Paul Hickey, the CEO, emphasized the market potential of this technology, which could reduce dependence on medications and enhance personalized treatment approaches.